skip to Main Content

About Us

Avectas is accelerating the future of cell therapy through an easy-to-integrate and flexible delivery platform that manufactures healthier and more functional cells for patients. The Avectas non-viral delivery platform excels at complex editing and challenging cargo delivery, ensuring the realization of the next generation of cell therapies. Our vision is to position the non-viral Solupore cell engineering technology to be integrated into manufacturing processes, including complex gene editing, for multiple autologous and allogeneic therapies.

Our Values

We strive for excellence and our commitment to innovation encourages a ‘fail fast’ philosophy and promotes a culture of transparency and ownership of mistakes made in the pursuit of challenging objectives.


Maintains optimal cell health & phenotype


Enhanced cell function after payload delivery

handle with care

Ability to apply payload delivery for a wide range of applications


Easy to integrate to your existing processes


Available as cGMP instrument by 2H 2023

Contact Avectas

Partnerships are essential to ensure better patient outcomes, and we are actively seeking to engage with companies and researchers who are developing these lifesaving gene modified cell therapy products. If you would like to learn more about working with Avectas and our cell engineering technology, get in touch with us.

Join Mailing List

Learn about our non-viral delivery platform including application notes, upcoming webinars, new resources and events.